ArticleBMC medicine2026
Smartphone-based lightweight AI system for real-time multiple anterior segment disease screening: development and real-world validation.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundAnterior segment diseases are a major global cause of preventable blindness, especially in regions with limited access to specialized ophthalmic care. Diagnosis typically requires slit-lamp biomicroscopy, creating a significant access bottleneck in primary care and rural settings. Existing AI solutions often lack the efficiency and generalizability necessary for widespread mobile deployment and primarily focus on individual conditions, failing to meet the demand for scalable, multi-disease screening platforms.
methodsWe developed the Intelligent Detection System (IDS), a smartphone-compatible AI platform for real-time, automated, multi-disease screening of anterior segment diseases. The core model, Eye-YOLO, is a novel, lightweight deep learning model optimized for standard smartphone images. IDS integrates image quality assessment and urgency classification. The model was rigorously trained on a large, heterogeneous multi-center dataset of 24,671 images (comprising 17,853 slit-lamp and 6,818 smartphone images) collected from three tertiary hospitals in China. IDS was prospectively deployed and validated via a widely accessible WeChat Mini Program for community screening.
resultsEye-YOLO achieved a mean average precision of 0.816 with an exceptionally compact architecture (2.77 million parameters and 7.3G FLOPs), enabling real-time inference at 131 FPS on mobile devices. In controlled testing, IDS demonstrated high diagnostic performance (93.50% accuracy; AUC = 0.9837) with consistent performance across multiple smartphone brands (AUC > 0.95). Crucially, with AI assistance, junior ophthalmologists achieved an accuracy of 93.79% (AUC 0.8984), compared with 95.79% for senior experts. In real-world external validation via the WeChat Mini Program, IDS achieved 98.25% accuracy.
conclusionsIDS provides a highly efficient, robust, and globally scalable framework for multi-disease anterior segment screening using ubiquitous smartphone technology. Its deployment through a widely accessible mobile platform offers a promising public health solution that facilitates early detection and triage, with the potential to improve access to ophthalmic care between specialized centers and primary care settings.
trial registrationChinese Clinical Trial Registry: ChiCTR2200060808.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.